Table 4. Effect upon peripheral blood count.
Effect upon peripheral blood count.
| Time | Day 0 | Day 45 | Day 88 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Immune category | Total | + | − | Total | + | − | Total | + | − |
| n (%) | 24 (100) | 5 (26) | 9 (38) | 22 (100) | 5 (23) | 9 (41) | 15 (100) | 5 (33) | 6 (40) |
| WBC (×106/ml) | 7.1 ± 1.8 | 5.6 ± 0.9 | 7.1 ± 1.5 | 7.4 ± 2.0 | 6.3 ± 1.8 | 6.5 ± 1.2 | 9.4 ± 4.5 | 5.8 ± 1.0 | 10.6 ± 5.0 |
| Neutrophils (×106/ml) | 4.7 ± 1.4 | 3.6 ± 1.0 | 4.8 ± 0.9 | 5.3 ± 1.6* | 4.2 ± 1.4 | 4.9 ± 1.3 | 7.1 ± 4.3* | 4.1 ± 0.6 | 8.1 ± 4.6 |
| Lymphocytes (×106/ml) | 1.5 ± 0.8 | 1.4 ± 0.7 | 1.5 ± 0.6 | 1.4 ± 0.7* | 1.4 ± 0.6 | 1.2 ± 0.7 | 1.3 ± 0.6* | 1.1 ± 0.4 | 1.4 ± 0.4 |
| Monocytes (×106/ml) | 0.6 ± 0.2 | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.6 ± 0.3 | 0.5 ± 0.1 | 0.5 ± 0.2 | 0.6 ± 0.3 | 0.5 ± 0.1 | 0.7 ± 0.3 |
Mean absolute cell count ± standard deviation are shown. “ +” = IFN-γ immune response observed by Day 88, “−“ = immune response not observed. 13 patients were not evaluable for immunity. ‘Day 0’ is day of cytoxan pretreatment. Day 45 and 88 are ±3 days.
Asterisks indicate p < 0.05, with each timepoint compared to pretreatment level by Wilcoxon signed rank.
No significant differences were observed between “+’ and “−“ groups by Wilcoxon rank-sum